Bank of America Corp DE Has $101.89 Million Holdings in Medpace Holdings, Inc. $MEDP

Bank of America Corp DE lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 212,183 shares of the company’s stock after purchasing an additional 1,487 shares during the quarter. Bank of America Corp DE owned 0.74% of Medpace worth $101,888,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of MEDP. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace during the fourth quarter worth $30,000. Elyxium Wealth LLC acquired a new stake in Medpace in the fourth quarter valued at $30,000. Quarry LP bought a new position in shares of Medpace during the third quarter worth about $35,000. Bayban bought a new position in Medpace during the 4th quarter worth approximately $44,000. Finally, Core Wealth Advisors LLC acquired a new position in Medpace in the fourth quarter valued at $47,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on MEDP shares. Truist Financial raised their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Royal Bank Of Canada boosted their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 price target on Medpace in a report on Thursday, July 23rd. BMO Capital Markets boosted their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Finally, TD Cowen boosted their target price on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $584.18.

Medpace Stock Up 1.0%

Shares of Medpace stock opened at $590.67 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The business has a 50 day moving average price of $522.14 and a 200-day moving average price of $492.78. The company has a market cap of $16.49 billion, a PE ratio of 34.62, a price-to-earnings-growth ratio of 2.61 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insider Buying and Selling

In related news, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the transaction, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. The trade was a 10.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 31,087 shares of company stock valued at $16,203,054. 20.50% of the stock is owned by insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.